Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

[1]  G. Rimbach,et al.  Determinants of paraoxonase 1 status: genes, drugs and nutrition. , 2011, Current medicinal chemistry.

[2]  A. Tsatsakis,et al.  Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases. , 2011, Toxicology and applied pharmacology.

[3]  L. Novotný,et al.  Organophosphate hydrolases as catalytic bioscavengers of organophosphorus nerve agents. , 2011, Toxicology letters.

[4]  R. Beyer,et al.  Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  Asa Bradman,et al.  Association of Organophosphate Pesticide Exposure and Paraoxonase with Birth Outcome in Mexican-American Women , 2011, PloS one.

[6]  M. Bartels,et al.  In Vitro Age-Dependent Enzymatic Metabolism of Chlorpyrifos and Chlorpyrifos-Oxon in Human Hepatic Microsomes and Chlorpyrifos-Oxon in Plasma , 2011, Drug Metabolism and Disposition.

[7]  D. Barr,et al.  Prenatal Exposure to Organophosphates, Paraoxonase 1, and Cognitive Development in Childhood , 2011, Environmental health perspectives.

[8]  Sudhir Kumar Jain,et al.  Paraoxonase-1 genetic polymorphisms and susceptibility to DNA damage in workers occupationally exposed to organophosphate pesticides. , 2011, Toxicology and applied pharmacology.

[9]  L. Costa,et al.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. , 2011, Biochemical pharmacology.

[10]  M. Cebrián,et al.  Interaction between organophosphate pesticide exposure and PON1 activity on thyroid function. , 2010, Toxicology and applied pharmacology.

[11]  N. Cherry,et al.  ‘Dippers' flu’ and its relationship to PON1 polymorphisms , 2010, Occupational and Environmental Medicine.

[12]  N. Holland,et al.  PON1 and Neurodevelopment in Children from the CHAMACOS Study Exposed to Organophosphate Pesticides in Utero , 2010, Environmental health perspectives.

[13]  C. Brewin,et al.  Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides. , 2010, Neurotoxicology and teratology.

[14]  N. Holland,et al.  Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. , 2010, Toxicology and applied pharmacology.

[15]  R. Vemulapalli,et al.  Evaluation of Cross-Reactive Cell-Mediated Immune Responses among Human, Bovine and Porcine Adenoviruses , 2010, Gene Therapy.

[16]  B. Ritz,et al.  Paraoxonase 1, Agricultural Organophosphate Exposure, and Parkinson Disease , 2010, Epidemiology.

[17]  T. Magliery,et al.  Dramatic differences in organophosphorus hydrolase activity between human and chimeric recombinant mammalian paraoxonase-1 enzymes. , 2009, Biochemistry.

[18]  J. Joven,et al.  Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity. , 2009, Mini reviews in medicinal chemistry.

[19]  Gerald van Belle,et al.  Serum Cholinesterase Inhibition in Relation to Paraoxonase-1 (PON1) Status among Organophosphate-Exposed Agricultural Pesticide Handlers , 2009, Environmental health perspectives.

[20]  P. Goldschmidt-Clermont,et al.  The paraoxonase gene family and atherosclerosis , 2009, Current atherosclerosis reports.

[21]  L. Costa,et al.  Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. , 2009, Toxicology and applied pharmacology.

[22]  J. Joven,et al.  The paraoxonases: role in human diseases and methodological difficulties in measurement , 2009, Critical reviews in clinical laboratory sciences.

[23]  G. Jarvik,et al.  Paraoxonase 1 (PON1) status and substrate hydrolysis. , 2009, Toxicology and applied pharmacology.

[24]  G. Jarvik,et al.  Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate Substrates , 2008, Circulation. Cardiovascular genetics.

[25]  S. Scherer,et al.  Dynamic variation in allele-specific gene expression of Paraoxonase-1 in murine and human tissues. , 2008, Human molecular genetics.

[26]  R. Stevens,et al.  Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning , 2008, Proceedings of the National Academy of Sciences.

[27]  V. Emmel,et al.  Evaluation of genetic damage in a Brazilian population occupationally exposed to pesticides and its correlation with polymorphisms in metabolizing genes. , 2008, Mutagenesis.

[28]  J. Joven,et al.  Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. , 2008, Free radical biology & medicine.

[29]  R. Haley,et al.  Dominant Role of Paraoxonases in Inactivation of the Pseudomonas aeruginosa Quorum-Sensing Signal N-(3-Oxododecanoyl)-l-Homoserine Lactone , 2008, Infection and Immunity.

[30]  N. Cherry,et al.  GST, CYP and PON1 polymorphisms in farmers attributing ill health to organophosphate-containing sheep dip , 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[31]  N. Holland,et al.  PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity , 2006, Pharmacogenetics and genomics.

[32]  K. Beckman,et al.  Paraoxonase Polymorphisms, Haplotypes, and Enzyme Activity in Latino Mothers and Newborns , 2006, Environmental health perspectives.

[33]  E. Greenberg,et al.  Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. , 2005, FEMS microbiology letters.

[34]  A. Tward,et al.  Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism , 2005, Pharmacogenetics and genomics.

[35]  R. Sunahara,et al.  Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains additional text, figures, and references. Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M , 2005, Journal of Lipid Research.

[36]  H. Checkoway,et al.  Risk of Brain Tumors in Children and Susceptibility to Organophosphorus Insecticides: The Potential Role of Paraoxonase (PON1) , 2005, Environmental health perspectives.

[37]  L. Costa,et al.  Modulation of paraoxonase (PON1) activity. , 2005, Biochemical pharmacology.

[38]  R. Edwards,et al.  Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon , 2005, Pharmacogenetics and genomics.

[39]  Dan S. Tawfik,et al.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes , 2004, Nature Structural &Molecular Biology.

[40]  G. Jarvik,et al.  Determination of Paraoxonase 1 Status and Genotypes at Specific Polymorphic Sites , 2004, Current protocols in toxicology.

[41]  J. Witte,et al.  Comparison of missing data approaches in linkage analysis , 2003, BMC Genetics.

[42]  D. Sok,et al.  Oxidative Inactivation of Paraoxonase1, an Antioxidant Protein and its Effect on Antioxidant Action , 2003, Free radical research.

[43]  G. Jarvik,et al.  Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. , 2003, Annual review of medicine.

[44]  E. Birman-Deych,et al.  In utero pesticide exposure, maternal paraoxonase activity, and head circumference. , 2003, Environmental health perspectives.

[45]  M. Khoury,et al.  Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease , 2003 .

[46]  L. Seeff,et al.  Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. , 2003, Metabolism: clinical and experimental.

[47]  M. Hotopf,et al.  Paraoxonase in Persian Gulf War Veterans , 2003, Journal of occupational and environmental medicine.

[48]  A. Tward,et al.  Expression of human paraoxonase (PON1) during development. , 2003, Pharmacogenetics.

[49]  R. Pannbacker.  Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects , 2003 .

[50]  Jia Chen,et al.  Increased influence of genetic variation on PON1 activity in neonates. , 2003, Environmental health perspectives.

[51]  C. Carlson,et al.  Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. , 2003, Pharmacogenetics.

[52]  J. Paulauskis,et al.  Association Between Human Paraoxonase Gene Polymorphism and Chronic Symptoms in Pesticide-Exposed Workers , 2003, Journal of occupational and environmental medicine.

[53]  N. Cherry,et al.  Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. , 2003, Pharmacogenetics.

[54]  A. Khalil,et al.  PON1 Paraoxonase Activity is Reduced During HDL Oxidation and is an Indicator of HDL Antioxidant Capacity , 2003, Free radical research.

[55]  G. Fonarow,et al.  Paraoxonase and coronary heart disease. , 2002, Current opinion in lipidology.

[56]  C Timchalk,et al.  Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. , 2002, Toxicology letters.

[57]  Nicola Cherry,et al.  Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip , 2002, The Lancet.

[58]  G. Franceschini,et al.  Enzymatically Active Paraoxonase-1 Is Located at the External Membrane of Producing Cells and Released by a High Affinity, Saturable, Desorption Mechanism* , 2002, The Journal of Biological Chemistry.

[59]  T. Shinozuka,et al.  Expression of paraoxonase isoform did not confer protection from acute sarin poisoning in the Tokyo subway terrorist attack , 2001, International Journal of Legal Medicine.

[60]  P. Durrington,et al.  Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[61]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[62]  R. Haley,et al.  Gene therapy to prevent organophosphate intoxication. , 2001, Toxicology and applied pharmacology.

[63]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[64]  A. Tward,et al.  Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. , 2000, Pharmacogenetics.

[65]  C. Pope,et al.  Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[66]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[67]  M. Mackness,et al.  Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. , 2000, Biochemical and biophysical research communications.

[68]  Y. Ikeda,et al.  A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. , 2000, Atherosclerosis.

[69]  V. Moser,et al.  Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and methamidophos. , 2000, Neurotoxicology.

[70]  C. Furlong.  PON1 status and neurologic symptom complexes in Gulf War veterans. , 2000, Genome research.

[71]  I. Leviev,et al.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[72]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[73]  B. La Du,et al.  Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[74]  R. Haley,et al.  Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. , 1999, Toxicology and applied pharmacology.

[75]  V. Moser,et al.  Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[76]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[77]  P. Durrington,et al.  Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification , 1998, FEBS letters.

[78]  C. Pope,et al.  Age-related differences in sensitivity to organophosphorus pesticides. , 1997, Environmental toxicology and pharmacology.

[79]  C. Disteche,et al.  Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. , 1997, Pharmacogenetics.

[80]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[81]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[82]  J. Chambers,et al.  Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. , 1995, Toxicology letters.

[83]  N. Masuda,et al.  Sarin poisoning in Tokyo subway , 1995, The Lancet.

[84]  Ryozo Nagai,et al.  Sarin poisoning in Tokyo subway , 1995, The Lancet.

[85]  L. Costa,et al.  Paraoxonase protects against chlorpyrifos toxicity in mice. , 1995, Toxicology letters.

[86]  L. Costa,et al.  Serum paraoxonase status: a major factor in determining resistance to organophosphates. , 1993, Journal of toxicology and environmental health.

[87]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[88]  C. Furlong,et al.  Purification of rabbit and human serum paraoxonase. , 1991, Biochemistry.

[89]  R. Humbert,et al.  Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. , 1991, Biochemistry.

[90]  G. Omenn,et al.  Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. , 1990, Toxicology and applied pharmacology.

[91]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.

[92]  A. Motulsky,et al.  Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. , 1983, American journal of human genetics.

[93]  D. Evans,et al.  Genetic polymorphism and interethnic variability of plasma paroxonase activity. , 1976, Journal of medical genetics.

[94]  S. D. Murphy,et al.  The influence of age on the toxicity and metabolism of methyl parathion and parathion in male and female rats. , 1975, Toxicology and applied pharmacology.

[95]  D. S. Stephens,et al.  Perinatal development of human blood esterases , 1973, Clinical pharmacology and therapeutics.

[96]  S. D. Murphy,et al.  Carboxylesterase inhibition as an indicator of malathion potentiation in mice. , 1971, The Journal of pharmacology and experimental therapeutics.

[97]  K. Augustinsson,et al.  AGE VARIATION IN PLASMA ARYLESTERASE ACTIVITY IN CHILDREN. , 1963, Clinica chimica acta; international journal of clinical chemistry.

[98]  A. Mazur.  An enzyme in animal tissues capable of hydrolysing the phosphorus-fluorine bond of alkyl fluorophosphates. , 1946, The Journal of biological chemistry.

[99]  Ahmet Tugrul Bayrak,et al.  Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis. , 2012, Journal of atherosclerosis and thrombosis.

[100]  Yushui Ma,et al.  Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies. , 2012, Molecular genetics and metabolism.

[101]  J. Albers,et al.  Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers , 2010, Journal of Exposure Science and Environmental Epidemiology.

[102]  L. Costa,et al.  Paraoxonase (PON1): from toxicology to cardiovascular medicine. , 2005, Acta bio-medica : Atenei Parmensis.

[103]  B. La Du,et al.  Pharmacogenetics of paraoxonases: a brief review , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[104]  C. Wahlestedt.  Array of possibilities. , 2003, Pharmacogenetics.

[105]  H. Sox,et al.  Depleted uranium, pyridostigmine bromide, sarin, vaccines , 2000 .

[106]  M. Maines.  Current protocols in toxicology , 1999 .

[107]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[108]  M. Hooper,et al.  Maturational differences in chlorpyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. , 1996, Journal of biochemical toxicology.

[109]  T. Ma,et al.  Role of detoxication pathways in acute toxicity levels of phosphorothionate insecticides in the rat. , 1994, Life sciences.

[110]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[111]  A. Smolen,et al.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[112]  G. Omenn,et al.  Species Differences in Serum Paraoxonase Correlate with Sensitivity to Paraoxon Toxicity , 1987 .

[113]  W. Aldridge.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. , 1953, The Biochemical journal.